You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for Patent: 8,475,780

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,475,780 protect, and when does it expire?

Patent 8,475,780 protects VELTASSA and is included in one NDA.

This patent has ninety-six patent family members in seventeen countries.

Summary for Patent: 8,475,780

Title:	Ion binding polymers and uses thereof
Abstract:	The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s):	Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Klaerner; Gerrit (Los Gatos, CA), Buysse; Jerry M. (Los Altos, CA), Liu; Mingjun (Campbell, CA)
Assignee:	Relypsa, Inc. (Redwood City, CA)
Application Number:	13/015,134
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,475,780
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,475,780

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-001	Oct 21, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,475,780

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1732523	⤷ Sign Up	300924	Netherlands	⤷ Sign Up
European Patent Office	2269589	⤷ Sign Up	CA 2018 00003	Denmark	⤷ Sign Up
European Patent Office	1732523	⤷ Sign Up	300925	Netherlands	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.